Companies Atara Biotherapeutics, Inc.
Atara Biotherapeutics (ATRA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Atara Biotherapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,277,691FY2023
- $1,573,716FY2024
- $1,068,069FY2025
CEO total pay was $1,068,069 in fiscal 2025, down from $1,573,716 in fiscal 2024.
FY2025: salary $668,800 · bonus $390,000 · stock awards $0 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| AnhCo Nguyen | $668,800 | $390,000 | $0 | $0 | $0 | $0 | $9,269 | $1,068,069 |
| President and Chief Executive Officer | ||||||||
| Eric Hyllengren | 132,000 | 58,500 | 250,949 | 0 | 0 | 0 | 600,918 | 1,042,367 |
| Former Executive Vice President, Chief Financial Officer and Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| AnhCo Nguyen | $1,068,069 | $1,573,716 | $2,277,691 | ↓ −505,647 |
| Eric Hyllengren | 1,042,367 | 926,137 | — | ↑ +116,230 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our philosophy in setting compensation policies for executive officers has two primary objectives: (i) to attract and retain talented and skilled executives by paying for performance; and (ii) to align compensation of our executives with the interests of our stockholders through an appropriate mix of short-term and long-term compensation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Eric Hyllengren | RSU | 2025-01-01 | — | — | 34,050 | — | — |
Vehicle mix — grant-date fair value by award type
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| AnhCo Nguyen | RSU | 150 | — | $2,714 |
| AnhCo Nguyen | Option | 281 | 255.25 | — |
| AnhCo Nguyen | RSU | 513 | — | 9,280 |
| AnhCo Nguyen | Option | 1,157 | 97.75 | — |
| AnhCo Nguyen | RSU | 3,375 | — | 61,054 |
| AnhCo Nguyen | RSU | 30,000 | — | 542,700 |
Director compensation
No director compensation table is on file for fiscal year 2025.
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $300,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | 3x base salary for non-employee directors |
Peer group, and who names Atara Biotherapeutics as a peer
Companies that benchmark against ATRA
3 companies name ATRA as a compensation peer
The list of companies that name ATRA as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Atara Biotherapeutics, Inc. | 2025 | AnhCo Nguyen | $668,800 | $0 | $0 | $0 | $1,068,069 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 3,526,411 | 44,481 | 4,532 | 98.75% | Passed |
| 2025 | 2025-06-10 | 2,979,311 | 43,445 | 13,284 | 98.56% | Passed |
| 2024 | 2024-06-10 | 63,970,487 | 6,810,564 | 350,321 | 90.38% | Passed |
| 2023 | 2023-05-31 | 71,805,771 | 2,174,272 | 167,122 | 97.06% | Passed |
| 2022 | 2022-06-23 | 78,488,147 | 2,362,933 | 49,351 | 97.08% | Passed |
| 2021 | 2021-06-08 | 64,159,489 | 1,216,269 | 175,925 | 98.14% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | 98.75%a |
| 2025 | 2025-06-10 | 98.56%b |
| 2024 | 2024-06-10 | 90.38%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Greater-than-10% holder | 2026-05-07 | A | 507,407 | $9 | $4,744,255 | Common | Form 4 ↗ |
| Panacea Innovation Ltd | Greater-than-10% holder | 2026-05-07 | D | 313,446 | 10 | 3,165,021 | Common | Form 4 ↗ |
| Yanina Grant-Huerta | Chief Accounting Officer | 2026-05-18 | D | 2,414 | 9 | 22,036 | Common | Form 4 ↗ |
| AnhCo Nguyen | Director | 2026-05-18 | D | 5,241 | 9 | 47,845 | Common | Form 4 ↗ |
| Matthew K. Fust | Director | 2026-06-09 | A | 12,000 | 0 | 0 | Common | Form 4 ↗ |
| William K. Heiden | Director | 2026-06-09 | A | 12,000 | 0 | 0 | Common | Form 4 ↗ |
| Gregory Austin Ciongoli | Director | 2026-06-09 | A | 12,000 | 0 | 0 | Common | Form 4 ↗ |
| Brian N. Cherry | Director | 2026-06-11 | A | 24,000 | 0 | 0 | Common | Form 4 ↗ |
| Redmile Group, LLC | Director | 2026-07-22 | D | 55,387 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Redmile Group, LLC | Director | 2026-07-22 | D | 38,735 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Redmile Group, LLC | Director | 2026-07-22 | D | 101,089 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Redmile Group, LLC | Director | 2026-07-22 | D | 60 | — | — | Common, indirect | Form 4 ↗ |
| Redmile Group, LLC | Director | 2026-07-22 | A | 195,211 | — | — | Common, indirect | Form 4 ↗ |
| AnhCo Nguyen | Director | 2026-08-17 | D | 5,062 | 8 | 40,883 | Common | Form 4 ↗ |
| Brian N. Cherry | Director | 2026-09-04 | A | 104,166 | 10 | 999,994 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (24 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, AnhCo Nguyen. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table” · page 39. As printed: 1,068,069. View filing ↗
- Section 01, Eric Hyllengren. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 1,042,367. View filing ↗
- Section 03, Eric Hyllengren RSU. DEF 14A, filed 2026-04-24. Section “INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-16. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 02, EcoR1 Capital, LLC 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Panacea Innovation Ltd 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yanina Grant-Huerta 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, AnhCo Nguyen 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew K. Fust 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William K. Heiden 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory Austin Ciongoli 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian N. Cherry 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Redmile Group, LLC 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Redmile Group, LLC 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Redmile Group, LLC 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Redmile Group, LLC 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Redmile Group, LLC 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, AnhCo Nguyen 2026-08-17. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian N. Cherry 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: 98.75% (votes for as printed: 3,526,411). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-11. Item 5.07 · say-on-pay result. As reported: 98.56% (votes for as printed: 2,979,311). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-11. Item 5.07 · say-on-pay result. As reported: 90.38% (votes for as printed: 63,970,487). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Atara Biotherapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Atara Biotherapeutics, Inc.'s own proxy. As printed: 1,068,069. View filing ↗